A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors. - Kebenko M; Goebeler ME; Wolf M; Hasenburg A; Seggewiss-Bernhardt R; Ritter B; Rautenberg B; Atanackovic D; Kratzer A; Rottman JB; Friedrich M; Vieser E; et al. (Oncoimmunology, 2018)